These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22777686)

  • 21. Both Reversible Self-Association and Structural Changes Underpin Molecular Viscoelasticity of mAb Solutions.
    Sarangapani PS; Weaver J; Parupudi A; Besong TMD; Adams GG; Harding SE; Manikwar P; Castellanos MM; Bishop SM; Pathak JA
    J Pharm Sci; 2016 Dec; 105(12):3496-3506. PubMed ID: 27793346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical Perspective on Opalescence and Liquid-Liquid Phase Separation in Protein Solutions.
    Raut AS; Kalonia DS
    Mol Pharm; 2016 May; 13(5):1431-44. PubMed ID: 27017836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No Touching! Abrasion of Adsorbed Protein Is the Root Cause of Subvisible Particle Formation During Stirring.
    Sediq AS; van Duijvenvoorde RB; Jiskoot W; Nejadnik MR
    J Pharm Sci; 2016 Feb; 105(2):519-529. PubMed ID: 26869415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody.
    Deokar V; Sharma A; Mody R; Volety SM
    J Pharm Sci; 2020 Dec; 109(12):3579-3589. PubMed ID: 32946895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viscosity of concentrated therapeutic protein compositions.
    Jezek J; Rides M; Derham B; Moore J; Cerasoli E; Simler R; Perez-Ramirez B
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1107-17. PubMed ID: 22014592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the NISTmAb Reference Material using small-angle scattering and molecular simulation : Part II: Concentrated protein solutions.
    Castellanos MM; Mattison K; Krueger S; Curtis JE
    Anal Bioanal Chem; 2018 Mar; 410(8):2161-2171. PubMed ID: 29423596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Well Do Low- and High-Concentration Protein Interactions Predict Solution Viscosities of Monoclonal Antibodies?
    Woldeyes MA; Qi W; Razinkov VI; Furst EM; Roberts CJ
    J Pharm Sci; 2019 Jan; 108(1):142-154. PubMed ID: 30017887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.
    Sánchez-Félix M; Burke M; Chen HH; Patterson C; Mittal S
    Adv Drug Deliv Rev; 2020 Dec; 167():66-77. PubMed ID: 32473188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
    Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ
    J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective.
    Narasimhan C; Mach H; Shameem M
    Ther Deliv; 2012 Jul; 3(7):889-900. PubMed ID: 22900469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of colloidal stability of high concentration protein formulations.
    Garidel P; Blume A; Wagner M
    Pharm Dev Technol; 2015 May; 20(3):367-74. PubMed ID: 24392929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temperature Dependence of Protein Solution Viscosity and Protein-Protein Interactions: Insights into the Origins of High-Viscosity Protein Solutions.
    Woldeyes MA; Qi W; Razinkov VI; Furst EM; Roberts CJ
    Mol Pharm; 2020 Dec; 17(12):4473-4482. PubMed ID: 33170708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amino Acid-Based Advanced Liquid Formulation Development for Highly Concentrated Therapeutic Antibodies Balances Physical and Chemical Stability and Low Viscosity.
    Kemter K; Altrichter J; Derwand R; Kriehuber T; Reinauer E; Scholz M
    Biotechnol J; 2018 Jul; 13(7):e1700523. PubMed ID: 29663661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.
    Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K
    Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications.
    Bahrenburg S; Karow AR; Garidel P
    Biotechnol J; 2015 Apr; 10(4):610-22. PubMed ID: 25641961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.
    Tessier PM; Wu J; Dickinson CD
    Expert Opin Drug Deliv; 2014 Apr; 11(4):461-5. PubMed ID: 24444112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.
    Chen B; Bautista R; Yu K; Zapata GA; Mulkerrin MG; Chamow SM
    Pharm Res; 2003 Dec; 20(12):1952-60. PubMed ID: 14725359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection.
    Bowen M; Armstrong N; Maa YF
    J Pharm Sci; 2012 Dec; 101(12):4433-43. PubMed ID: 23001898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.